SAN DIEGO, CA—“The future of cancer vaccines is now.” That’s the first thing that Geneos Therapeutics’ CEO and president, Niranjan Sardesai, PhD, said in an interview with GEN Edge at AACR 2024. “We’re at a point in time where there is no longer any doubt that...
RNA-based immunizing agents have enriched the repertoire of technologies used for vaccine development. An analysis of the active clinical trials in early Phase I and Phase I during the year of 2023 illustrates this point. A total of 161 active vaccine trials were...
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or “Company”) announced that it has received a Notice of Allowance from the Japanese Patent Office for a Patent (“Patent”) for inducing an antibody immune...
Moderna has touted the possibility of an accelerated approval for its Merck-partnered cancer vaccine by 2025. But according to executives, three things need to happen first. Merck and Moderna made news in December 2022 when they unveiled Phase II data suggesting their...
Credit: Pixabay/CC0 Public Domain Vaccines that protect against severe illness, death and lingering long COVID symptoms from a coronavirus infection were linked to small increases in neurological, blood, and heart-related conditions in the largest global vaccine...
